Vaxcyte

At the Wells Fargo conference, Vaxcyte presented a strategy aimed at broader serotype coverage and stronger immune responses. Lead candidate VAX-31 is in Phase III; the company said OPUS-1 data could be available by the end of October 2024 and is expected to show coverage of around 95% of circulating pneumococcal strains (Prevnar 20 about 60%, CAPVAXIVE around 82%). Vaxcyte cites Phase II data showing roughly a 25% higher average immune response and emphasizes its cell-free protein synthesis platform; VAX-A1 against group A streptococcus is in Phase I. The company is targeting approval by the end of 2028, contingent on manufacturing consistency, and expects OPUS-2/OPUS-3 results in the first half of 2025. » More on de.investing.com

CEO Grant Pickering surrendered 6,289 Vaxcyte shares in a non‑discretionary transaction to cover tax withholdings on vested RSUs, leaving him with roughly 447,000 directly held shares and 266,430 indirectly held shares in trusts. Vaxcyte is preparing for topline OPUS-1 Phase 3 data on VAX-31 in the fourth quarter, a pivotal readout versus Pfizer and Merck that will determine filing timelines. The company reported high cash burn ($284.3m in the June quarter) but holds about $2.5bn in cash, making the trial outcome critical for its commercial prospects and cash runway. » More on finance.yahoo.com

President and CFO Andrew Guggenhime surrendered 2,705 Vaxcyte shares to satisfy tax withholding on vested RSUs; he retains about 164,321 shares total. Vaxcyte held $2.51 billion in cash and investments at end-June while reporting a six-month net loss of $604.9 million and rising operating expenses as it prepares manufacturing and clinical milestones. The company is advancing its lead candidate VAX-24 with key readouts expected later in the year that could validate recent buildout or leave the firm having pre-funded a product still awaiting pivotal data. » More on finance.yahoo.com